This segment focuses on the research and development of novel therapeutics designed to stimulate the body's immune system to fight cancer. Werewolf Therapeutics leverages its proprietary PREDATOR platform to create conditionally activated molecules, known as INDUKINEs, that target the tumor microenvironment. Key R&D activities include preclinical studies, clinical trials (Phase 1 and Phase 2), and biomarker discovery. The therapeutic areas covered are advanced solid tumors, relapsed or refractory advanced or metastatic solid tumors, and lymphoma. The goal is to enhance efficacy and reduce systemic toxicity compared to conventional immunotherapies. The company has established collaborations with Merck and Jazz Pharmaceuticals to advance its pipeline. Future opportunities include expanding the application of the PREDATOR platform to other cancer types and developing combination therapies.